The dual-optimized CD19 antibody showed a significant higher tumor cell lysis of the B-ALL cell line SEM compared to CD19-DE, when FcγR-positive effector cells (ADCC) and the complement system (CDC) were present as effector components (Figure 4A). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.